https://www.statnews.com/2026/04/06/neurocrine-biosciences-soleno-therapeutics-acquisition-prader-willi-vykat/
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Apr 6, 2026 - As part of the deal, Neurocrine will pick up an approved drug for the rare disease Prader-Willi syndrome, which has seen a successful launch.
neurocrinebiosciencesbuytherapeuticsdeal
https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Apr 6, 2026 - VYKAT⢠XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy...
rare diseaseneurocrineacquiretherapeuticsexpanding
https://www.gapna.org/about/corporate-partners/neurocrine-biosciences-inc
Neurocrine Biosciences Inc. | Gerontological Advanced Practice Nurses Association (GAPNA)
advanced practiceneurocrinebiosciencesincnurses
https://www.namiwalks.org/pages/3390
Neurocrine
I'm supporting NAMI!
neurocrine
https://www.statnews.com/2026/04/06/biotech-news-stealth-biotech-stipple-bets-on-adcs/
Neurocrine, Stipple, Kezar, peptides, cancer: The Readout
Apr 6, 2026 - Today's biotech news includes how thin science fuels peptide hype, blowback to proposed NIH cuts, and a stealth biotech's secret ADCs
the readoutneurocrinepeptidescancer